



Dedicated to you

## Financial Statements

**Ceylon Hospitals PLC**

*For the 1st Quarter ended 30th June 2022*

**Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	<b>Group</b>		<b>Company</b>	
	<b>03 Months</b>	<b>03 Months</b>	<b>03 Months</b>	<b>03 Months</b>
	<b>Ended</b>	<b>Ended</b>	<b>Ended</b>	<b>Ended</b>
	<b>30/06/2022</b>	<b>30/06/2021</b>	<b>30/06/2022</b>	<b>30/06/2021</b>
	<b>Rs. '000</b>	<b>Rs. '000</b>	<b>Rs. '000</b>	<b>Rs. '000</b>
Revenue	<b>1,644,483</b>	1,880,131	<b>906,217</b>	1,259,665
Cost of Sales	<b>(620,676)</b>	(734,546)	<b>(342,590)</b>	(516,694)
Gross Profit	<b>1,023,808</b>	1,145,586	<b>563,627</b>	742,972
Other Operating Income	<b>(13,168)</b>	8,614	<b>8,806</b>	4,692
<b>Overheads</b>				
Administrative Expenses	<b>(621,428)</b>	(699,633)	<b>(397,893)</b>	(501,476)
Other Operating Expenses	<b>(196,650)</b>	(162,320)	<b>(120,496)</b>	(109,944)
Finance Cost	<b>(15,583)</b>	(23,872)	<b>(12,678)</b>	(22,767)
Finance Income	<b>65,340</b>	19,642	<b>213,155</b>	152,507
	<b>(768,321)</b>	(866,183)	<b>(317,912)</b>	(481,681)
Gain on Bargain Purchase	-	12,002	-	-
Share of Profit of an Equity Accounted Investee	-	13,263	-	-
Profit Before Taxation	<b>242,319</b>	313,282	<b>254,521</b>	265,983
Taxation	<b>(35,314)</b>	(83,542)	<b>(15,145)</b>	(41,766)
Net Profit after Taxation	<b>207,006</b>	229,740	<b>239,376</b>	224,217
<b>Other Comprehensive Income</b>				
<b>Items will not be reclassified to profit or loss</b>				
Net Change in Fair Value on Equity Investments at FVOCI	<b>(1,880)</b>	56	<b>1,660</b>	56
Other Comprehensive Income for the Year	<b>(1,880)</b>	56	<b>1,660</b>	56
<b>Total Comprehensive Income for the Year</b>	<b>205,125</b>	229,796	<b>241,036</b>	224,273
Profit Attributable to:				
Equity Holders of the Parent	<b>184,299</b>	193,691	<b>241,036</b>	224,217
Non-Controlling Interest	<b>22,706</b>	36,049	-	-
	<b>207,006</b>	229,740	<b>241,036</b>	224,217
Total Comprehensive Income Attributable to:				
Equity Holders of the Parent	<b>183,086</b>	193,747	<b>239,376</b>	224,273
Non-Controlling Interest	<b>22,039</b>	36,049	-	-
	<b>205,125</b>	229,796	<b>239,376</b>	224,273
<b>Earnings per Share - Basic</b>	<b>5.44</b>	5.72	<b>7.12</b>	6.62

The above figures are provisional and subject to audit.

**Consolidated Statement of Financial Position**

<b>GROUP</b>		<b>COMPANY</b>		<b>GROUP</b>		<b>COMPANY</b>	
Audited	Audited			Unaudited	Audited	Unaudited	Audited
As at	As at			As at	As at	As at	As at
31/03/2022	31/03/2022			30/06/2022	30/06/2021	30/06/2022	30/06/2021
Rs. '000	Rs. '000			Rs. '000	Rs. '000	Rs. '000	Rs. '000
<b>ASSETS</b>							
<b>Non-Current Assets</b>							
8,481,203	5,592,128	Property, Plant and Equipment		8,637,893	7,796,767	5,748,239	5,166,959
288,954	288,954	Right of Use Assets		273,264	206,644	273,264	206,644
-	1,457,821	Investments in Subsidiary		-	-	1,457,821	1,457,821
-	-	Investment in Equity Accounted Investee		-	-	-	-
272,923	71,416	Other Financial Assets		304,186	216,607	82,847	67,350
890	-	Prepaid Rent		1,760	853	-	-
9,043,970	7,410,319			9,217,103	8,220,870	7,562,170	6,898,773
<b>Current Assets</b>							
835,149	693,571	Inventories		996,593	632,693	806,117	505,034
306,454	214,955	Trade and Other Receivables		407,511	368,957	199,307	209,465
252,441	195,053	Prepayments		479,569	204,290	286,667	167,610
1,934	75,921	Amount Due from Related Parties		4,399	370	34,377	82,717
1,451,388	659,287	Other Financial Assets		1,551,226	824,417	771,808	130,407
13,278	13,259	Tax Refund Due		13,260	-	13,260	-
898,189	129,295	Cash and Cash Equivalents		361,135	811,655	124,725	303,714
3,758,833	1,981,341			3,813,693	2,842,382	2,236,259	1,398,946
12,802,803	9,391,660	<b>Total Assets</b>		13,030,797	11,063,252	9,798,430	8,297,720
<b>EQUITY AND LIABILITIES</b>							
<b>Equity Attributable to Equity holders of the parent</b>							
916,366	916,366	Stated Capital		916,366	916,366	916,366	916,366
2,691,662	2,134,544	Revaluation Reserve		2,691,662	2,691,662	2,134,544	2,134,544
65,868	600	Fair Value Reserve		64,655	68,492	2,260	184
3,873,950	2,695,436	Revenue Reserves		3,888,885	3,036,737	2,765,448	2,102,224
7,547,846	5,746,946			7,561,568	6,713,258	5,818,618	5,153,318
734,254	-	Non-Controlling Interests		714,061	727,986	-	-
8,282,100	5,746,946	<b>Total Equity</b>		8,275,629	7,441,244	5,818,618	5,153,318
<b>Non-Current Liabilities</b>							
1,701,501	1,606,247	Interest Bearing Loans and Borrowings		1,921,961	879,217	1,834,353	818,299
-	31,470	Deferred Revenue		-	-	30,129	32,925
177,998	156,790	Retirement Benefit Obligations		180,747	243,703	158,385	218,148
707,793	452,599	Deferred Tax Liabilities		711,252	646,650	452,599	440,809
2,587,292	2,247,106			2,813,959	1,769,569	2,475,466	1,510,181
<b>Current Liabilities</b>							
246,765	94,527	Bank Overdraft		256,995	304,588	84,960	246,890
306,060	248,830	Interest Bearing Loans and Borrowings		318,314	562,734	268,043	525,141
1,247,893	862,449	Trade and Other Payables		1,268,600	918,472	774,714	583,099
127,894	73,281	Taxation Payable		83,976	54,795	40,278	35,567
4,799	118,521	Amount Due to Related Parties		13,322	11,850	336,351	243,523
1,933,411	1,397,608			1,941,208	1,852,439	1,504,346	1,634,221
12,802,803	9,391,660	<b>Total Equity and Liabilities</b>		13,030,797	11,063,252	9,798,430	8,297,720

The above figures are provisional and subject to audit.

Signed  
**R K Thusitha**  
 Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements.  
 Signed for and on behalf of the Board by,

Signed  
**A E Tudawe**  
 Chairman

Signed  
**U D Tudawe**  
 Director

## STATEMENT OF CHANGES IN EQUITY

## Group

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Accumulated Profits Rs. '000	Total Rs. '000	Non-Controlling Interest Rs. '000	Total Rs. '000
<b>Balance as at 31st March 2021</b>	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,530
Net Profit for the Period	-	-	-	982,324	982,324	127,202	1,109,526
<b>Other Comprehensive Income</b>							
Deferred Tax Effect on Revaluation Gain	-	-	-	-	-	-	-
Actuarial Gain/ (Loss) on Gratuity Valuation	-	-	-	55,965	55,965	300	56,265
Deferred Tax effect on actuarial Loss on Gratuity Valuation	-	-	-	(6,342)	(6,342)	332	(6,010)
Prior Year Adjustments - Inventory Written off	-	-	-	(989)	(989)	(230)	(1,219)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	(2,568)	-	(2,568)	217	(2,351)
<b>Total Comprehensive Income for the Period</b>	-	-	(2,568)	1,030,958	1,028,390	127,821	1,156,211
<b>Transactions with Owners in their capacity as Owners</b>							
Non Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	127,301	127,301
Share Buy-back	-	-	-	(54)	(54)	-	(54)
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,495)	(221,888)
	-	-	-	(108,447)	(108,447)	13,806	(94,641)
<b>Balance as at 31st March 2022</b>	916,366	2,691,662	65,868	3,873,950	7,547,846	734,253	8,282,100
Net Profit for the Period	-	-	-	184,299	184,299	22,706	207,006
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVOCI	-	-	(1,213)	-	(1,213)	(667)	(1,880)
<b>Total Comprehensive Income for the Period</b>	-	-	(1,213)	184,299	183,086	22,039	205,125
<b>Transactions with Owners in their capacity as Owners</b>							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	-	-
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)	(42,231)	(211,595)
	-	-	-	(169,364)	(169,364)	(42,231)	(211,595)
<b>Balance as at 30th June 2022</b>	916,366	2,691,662	64,655	3,888,885	7,561,568	714,061	8,275,629

## Company

	Stated Capital Rs. '000	Revaluation Reserve Rs. '000	Fair Value Reserve Rs. '000	Accumulated Profits Rs. '000	Total Rs. '000
<b>Balance as at 31st March 2021</b>	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the Period	-	-	-	770,550	770,550
<b>Other Comprehensive Income</b>					
Actuarial Gain/ (Loss) on Gratuity Valuation	-	-	-	54,510	54,510
Deferred Tax Effect on Gratuity Valuation	-	-	-	(7,631)	(7,631)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	472	-	472
<b>Total Comprehensive Income for the Period</b>	-	-	472	817,429	817,901
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
	-	-	-	(108,393)	(108,393)
<b>Balance as at 31st March 2022</b>	916,366	2,134,544	600	2,695,436	5,746,946
Net Profit/(Loss) for the period	-	-	-	239,376	239,376
<b>Other Comprehensive Income</b>					
Net Change in Fair Value on Equity Investments at FVOCI	-	-	1,660	-	1,660
<b>Total Comprehensive Income for the Period</b>	-	-	1,660	239,376	241,036
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(169,364)	(169,364)
	-	-	-	(169,364)	(169,364)
<b>Balance as at 30th June 2022</b>	916,366	2,134,544	2,260	2,765,448	5,818,618

**Statement of Changes in Equity**  
**For the period ended 30th June 2021**

**Group**

	<b>Stated Capital Rs. '000</b>	<b>Revaluation Reserve Rs. '000</b>	<b>Fair Value Reserve Rs. '000</b>	<b>Accumulated Profits Rs. '000</b>	<b>Total Rs. '000</b>	<b>Non-Controlling Interest Rs. '000</b>	<b>Total Rs. '000</b>
<b>Balance as at 31st March 2020</b>	916,366	2,483,785	65,922	2,439,753	5,905,826	587,760	6,493,586
Net Profit for the Period	-	-	-	560,349	560,349	39,910	600,259
<b>Other Comprehensive Income</b>							
Deferred Tax Effect on Revaluation Gain	-	207,877	-	-	207,877	752	208,629
Actuarial Gain/ (Loss) on Gratuity Valuation	-	-	-	32,865	32,865	370	33,235
Deferred Tax Charge on actuarial Loss on Gratuity Valuation	-	-	-	(7,007)	(7,007)	(610)	(7,618)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	2,514	-	2,514	554	3,068
<b>Total Comprehensive Income for the Period</b>	<b>-</b>	<b>207,877</b>	<b>2,514</b>	<b>586,206</b>	<b>796,597</b>	<b>40,975</b>	<b>837,572</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Share of additional capital attributable to NCI	-	-	-	-	-	1,750	1,750
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)	(37,859)	(112,379)
	<b>-</b>	<b>-</b>	<b>-</b>	<b>(74,520)</b>	<b>(74,520)</b>	<b>(36,109)</b>	<b>(110,629)</b>
<b>Balance as at 31st March 2021</b>	<b>916,366</b>	<b>2,691,662</b>	<b>68,436</b>	<b>2,951,439</b>	<b>6,627,903</b>	<b>592,626</b>	<b>7,220,530</b>
Net Profit for the Period	-	-	-	193,691	193,691	36,049	229,740
<b>Other Comprehensive Income</b>							
Net Change in Fair Value on Equity Investments at FVOCI	-	-	56	-	56	-	56
<b>Total Comprehensive Income for the Period</b>	<b>-</b>	<b>-</b>	<b>56</b>	<b>193,691</b>	<b>193,747</b>	<b>36,049</b>	<b>229,796</b>
<b>Transactions with Owners in their capacity as Owners</b>							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	126,444	126,444
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(27,133)	(135,526)
	<b>-</b>	<b>-</b>	<b>-</b>	<b>(108,393)</b>	<b>(108,393)</b>	<b>99,311</b>	<b>(9,082)</b>
<b>Balance as at 30th June 2021</b>	<b>916,366</b>	<b>2,691,662</b>	<b>68,492</b>	<b>3,036,737</b>	<b>6,713,258</b>	<b>727,986</b>	<b>7,441,244</b>

**Company**

	<b>Stated Capital Rs. '000</b>	<b>Revaluation Reserve Rs. '000</b>	<b>Fair Value Reserve Rs. '000</b>	<b>Accumulated Profits Rs. '000</b>	<b>Total Rs. '000</b>
<b>Balance as at 31st March 2020</b>	916,366	1,931,063	-	1,588,064	4,435,493
Net Profit for the Period	-	-	-	446,118	446,118
<b>Other Comprehensive Income</b>					
Deferred Tax Effect on Revaluation Gain	-	203,481	-	-	203,481
Actuarial Gain/ (Loss) on Gratuity Valuation	-	-	-	31,090	31,090
Deferred Tax Effect on Gratuity Valuation	-	-	-	(4,353)	(4,353)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	128	-	128
<b>Total Comprehensive Income for the Period</b>	<b>-</b>	<b>203,481</b>	<b>128</b>	<b>472,855</b>	<b>676,464</b>
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)
	<b>-</b>	<b>-</b>	<b>-</b>	<b>(74,520)</b>	<b>(74,520)</b>
<b>Balance as at 31st March 2021</b>	<b>916,366</b>	<b>2,134,544</b>	<b>128</b>	<b>1,986,400</b>	<b>5,037,438</b>
Net Profit/(Loss) for the period	-	-	-	224,217	224,217
<b>Other Comprehensive Income</b>					
Net Change in Fair Value on Equity Investments at FVOCI	-	-	56	-	56
<b>Total Comprehensive Income for the Period</b>	<b>-</b>	<b>-</b>	<b>56</b>	<b>224,217</b>	<b>224,273</b>
<b>Transactions with Owners in their capacity as Owners</b>					
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)
	<b>-</b>	<b>-</b>	<b>-</b>	<b>(108,393)</b>	<b>(108,393)</b>
<b>Balance as at 30th June 2021</b>	<b>916,366</b>	<b>2,134,544</b>	<b>184</b>	<b>2,102,224</b>	<b>5,153,318</b>

## Statement of Cash Flows

Group Audited 12 Months Ended 31/03/2022 Rs '000	Company Audited 12 Months Ended 31/03/2022 Rs '000		Group Unaudited 3 Months Ended 30/06/2022 Rs '000	Audited 3 Months Ended 30/06/2021 Rs '000	Company Unaudited 3 Months Ended 30/06/2022 Rs '000	Audited 3 Months Ended 30/06/2021 Rs '000
<b>Cash Flows from/ (Used in) Operating Activities</b>						
1,388,911	902,276	Net Profit Before Income Tax Expenses	242,319	313,282	254,521	265,983
		Adjustments for :				
25,388	21,790	Inventory Write-off/(Net)	(1,015)	9,810	2,844	9,384
19,490	12,010	Bad Debts Write-off	190	300	190	300
339,848	185,027	Depreciation Charge	88,966	80,458	49,080	43,801
108,031	108,031	Amortisation of Right to use assets	27,844	25,991	27,844	25,991
(81,822)	(253,213)	Finance Income	(65,340)	(19,642)	(213,155)	(152,507)
80,567	70,786	Finance Cost	15,583	23,872	12,678	22,767
100	(1,790)	Amortisation of Deferred Rent	(870)	137	(1,343)	(336)
(5,202)	(5,202)	(Profit)/ Loss on Disposal of Property, Plant and Equipment	-	-	-	-
(32,917)	472	(Increase)/ Decrease in Financial Instruments	28,347	347	(1,208)	56
-	-	Foreign Exchange (Gain)/Loss	1,474	-	5,919	-
-	-	Reversal of provisions	(29,500)	-	(29,500)	-
(11,724)	-	Share of Profit of an Equity Accounted Investee	-	(13,263)	-	-
28,948	25,089	Provision for Defined Benefit Plans	9,750	9,530	8,100	8,100
1,859,618	1,065,276	Operating Profit before Working Capital Changes	317,748	430,821	115,969	223,539
(324,660)	(264,887)	(Increase)/Decrease in Inventories	(160,428)	(106,626)	(115,388)	(63,943)
(184,978)	(143,616)	(Increase)/Decrease in Trade and Other Receivables	(329,850)	(180,141)	(82,074)	(98,971)
576,763	477,733	Increase/(Decrease) in Trade and Other Payables	50,207	247,342	(58,236)	198,383
(171,712)	(51,357)	(Increase)/Decrease in Related Party Dues	6,059	(163,096)	259,373	66,849
1,755,031	1,083,150	Cash Generated from Operations	(116,264)	228,300	119,645	325,857
(51,361)	(41,581)	Finance Cost Paid	(15,583)	(17,802)	(12,678)	(16,698)
(37,567)	(30,868)	Defined Benefit Plan Costs Paid	(7,001)	(8,709)	(6,505)	(7,030)
(160,869)	(109,439)	Income Tax Paid	(75,756)	(79,982)	(48,148)	(48,093)
1,505,234	901,262	Net Cash from Operating Activities	(214,605)	121,807	52,314	254,036
<b>Cash Flows from/ (used in) Investing Activities</b>						
(1,109,961)	(697,335)	Acquisition of Property, Plant and Equipment	(245,657)	(162,877)	(205,191)	(127,393)
-	-	Acquisition of Right to use assets	-	-	-	-
8,750	8,750	Proceeds from Sale of Property, Plant and Equipment	-	290	-	-
(422,851)	(540,616)	(Acquisition)/ Disposal of other Investments	(161,328)	353,573	(121,083)	(7,671)
81,822	253,213	Income from Investments	65,340	19,642	213,155	152,507
(1,442,240)	(975,988)	Net Cash Flows from/ (used in) Investing Activities	(341,645)	210,628	(113,120)	17,443
<b>Cash Flows from/ (used in) Financing Activities</b>						
1,019,153	900,909	Receipts from Interest Bearing Loans and Borrowings	300,000	105,015	300,000	72,025
(740,022)	(699,802)	Re-payments to Interest Bearing Loans and Borrowing	(35,324)	(304,402)	(20,719)	(295,462)
(135,537)	(135,537)	Lease Rent Payment	(44,115)	(35,279)	(44,115)	(35,142)
(54)	-	Payment on share buyback	-	-	-	-
248,399	-	Non-Controlling Interest on Acquisition of Subsidiary	-	126,444	-	-
(221,888)	(108,393)	Dividends Paid	(211,595)	(135,526)	(169,364)	(108,393)
170,051	(42,823)	Net Cash Flows from/ (used in) Financing Activities	8,966	(243,747)	65,803	(366,972)
233,044	(117,549)	<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	(547,283)	88,688	4,997	(95,493)
418,379	152,317	<b>Cash and Cash Equivalents at the Beginning of the Year</b>	651,423	418,379	34,768	152,317
651,423	34,768	<b>Cash and Cash Equivalents at the End of the Year</b>	104,140	507,067	39,765	56,824
<b>Analysis of Cash and Cash Equivalents</b>						
(246,766)	(94,527)	Bank Overdraft	(256,995)	(304,588)	(84,960)	(246,890)
898,189	129,295	Cash in Hand and at Bank	361,135	811,655	124,725	303,714
651,423	34,768		104,140	507,067	39,765	56,824

**Explanatory Notes****01. CORPORATE INFORMATION**

Ceylon Hospitals PLC is a public limited liability company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

**02. INTERIM CONDENSED FINANCIAL STATEMENTS**

The financial statements for the quarter ended 30 June 2022, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

**03. APPROVAL OF FINANCIAL STATEMENTS**

The interim condensed financial statements of the Group and the Company for the period ended 30 June 2022 were authorised for issue by the Board of Directors on 10 August 2022.

**04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES****4.1 Basis of preparation**

The interim financial statements for the quarter ended 30 June 2022 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 March 2022.

**4.2 Fair value measurement and related fair value disclosures**

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 30 June 2022 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

**4.3 COVID - 19 impact assessment**

The Company has been in continuous operation although at reduced level subject to guidelines set out by the Government of Sri Lanka (GOSL) confirming to the regulations and guidelines issued by the GOSL, Ministry of Health (MOH) and other allied authorities.

No circumstances have arisen since the Balance Sheet date, which would require adjustment or disclosure in the interim Financial Statements other than what is stated above.

05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.

06. Related party transactions for the quarter ended 30 June 2022 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

**Related Party Transactions**  
**For the quarter ended 30 June 2022**

Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs.'000
Durdans Management Services Ltd	Ultimate Parent	Management fee	Recurrent	11,738
		Rendering of utilities and other cost	Recurrent	651
		<b>Total</b>		<b>12,389</b>
Durdans Medical and Surgical Hospital (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	7,025
		Rendering of medical services	Recurrent	100,190
		Rendering of utilities and other cost	Recurrent	118,530
		Purchases of Drugs and consumables	Recurrent	8,736
		Receiving of medical services	Recurrent	44,488
		Receiving of utilities and other cost	Recurrent	13,664
		<b>Total</b>		<b>292,633</b>
Durdans Heart Centre (Pvt) Ltd	Subsidiary	Sales of Drugs and consumables	Recurrent	1,364
		Rendering of medical services	Recurrent	27,616
		Rendering of utilities and other cost	Recurrent	24,699
		Purchases of Drugs and consumables	Recurrent	3,403
		Receiving of medical services	Recurrent	9,857
		Receiving of utilities and other cost	Recurrent	60
		<b>Total</b>		<b>66,999</b>
Amrak Institute of Medical Sciences (Pvt) Ltd	Subsidiary	Receiving of utilities and other cost	Recurrent	107
		<b>Total</b>		<b>107</b>
Ceygen Biotech (Pvt) Ltd	Equity Accounted Investee	Purchases of Drugs and consumables	Recurrent	147
		Receiving of utilities and other cost	Recurrent	-
		<b>Total</b>		<b>147</b>
Commercial Marketing Distributors (Pvt) Ltd	Affiliate	Purchases of Drugs and consumables	Recurrent	35,404
		<b>Total</b>		<b>35,404</b>
Tudawe Brothers (Pvt) Ltd	Affiliate	Rendering of medical services	Recurrent	38
		<b>Total</b>		<b>38</b>
Name of the Related Party	Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions Rs.'000
Tudawe Brothers (Pvt) Ltd	Affiliate	Project 2022 Construction Cost	Non Recurrent	40,352
		<b>Total</b>		<b>40,352</b>



**Share Information****Number of Shares Represented in Stated Capital**

Voting Shares	25,527,272
Non-Voting Shares	8,345,454
Total	<b>33,872,726</b>

**Public Shareholding as at 30th June 2022**

	<b>Voting</b>	<b>Non-Voting</b>
Number of shareholders	2,346	1,280
Number of shares	5,965,899	4,228,114
Holding Percentage	23.37%	50.66%
Float Adjusted Market Capitalisation (Rs Mn)	701	
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)	

**Directors' and Chief Executive Officer's Shareholding as at 30th June 2022**

	<b>Number of Shares</b>	
	<b>Voting</b>	<b>Non-Voting</b>
Mr. A. E. Tudawe	215,202	-
Mr. U. D. Tudawe	170,616	-
Dr. A. D. P. A. Wijegoonewardene	220,582	-
Mr. Y. N. R. Piyasena	501,000	-
Mr. A. S. Abeyewardene	1,440	1,200
Mr. A. D. B. Talwatte	1,000	-
Mr. A.V.R. De Silva Jayatilleke	100	-
Mr. A.S. Tudawe	48	1,000

**Market Prices recorded during the Quarter**

	<b>Highest Traded Price</b>		<b>Lowest Traded Price</b>		<b>Last Traded Price</b>	
	<b>2022/23</b>	<b>2021/22</b>	<b>2022/23</b>	<b>2021/22</b>	<b>2022/23</b>	<b>2021/22</b>
	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>
Voting	<b>139.00</b>	109.50	<b>100.00</b>	95.50	<b>117.50</b>	103.00
	<b>08/06/2022</b>	<b>19/05/2021</b>	<b>27/04/2022</b>	<b>27/04/2021</b>	<b>30/06/2022</b>	<b>30/06/2021</b>
Non - Voting	<b>115.00</b>	108.00	<b>81.00</b>	88.20	<b>98.90</b>	91.10
	<b>23/05/2022</b>	<b>18/05/2021</b>	<b>19/05/2022</b>	<b>09/04/2021</b>	<b>28/06/2022</b>	<b>30/06/2021</b>

**Per Share Ratios**

	<b>Group</b>		<b>Company</b>	
	<b>As at</b>	<b>As at</b>	<b>As at</b>	<b>As at</b>
	<b>30/06/2022</b>	<b>30/06/2021</b>	<b>30/06/2022</b>	<b>30/06/2021</b>
	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>	<b>Rs.</b>
Earnings Per Share	<b>5.44</b>	5.72	<b>7.12</b>	6.62
Net Assets Per Share	<b>223.23</b>	198.19	<b>171.78</b>	152.14

**Top 20 Shareholders Listed as at 30 June 2022****Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	17,471,382	68.44
Lawrance Tudawe Management Services (Pvt) Ltd	do	600,077	2.35
Mr. Y. N. R. Piyasena	do	501,000	1.96
Mr. Deen Mohamed Fazal Aslam	do	475,000	1.86
Galle Face Capital Partners PLC	do	400,000	1.57
Mr. Merrill J. Fernando	do	367,530	1.44
Mr. S. P. Tudawe (Deceased)	do	307,936	1.21
Cargo Boat Development Company PLC	do	305,485	1.20
MJF Holdings Ltd	do	270,981	1.06
Mr. D.G. Wijemanna	do	244,854	0.96
Mr. R.P. Weerasooriya	do	236,306	0.93
Mr. A. D. P. A. Wijegoonewardene	do	220,582	0.86
Mr. A. E. Tudawe	do	215,202	0.84
Mrs. H. K. Weerasinghe	do	200,000	0.78
Mrs. L. I. Weerasinghe	do	200,000	0.78
Ms. T. T. Weerasinghe	do	200,000	0.78
Mr. U. D. Tudawe	do	170,616	0.67
Mr. A. D. Tudawe	do	161,984	0.63
Mr. A.H. Munasinghe	do	86,326	0.34
Commercial Bank of Ceylon PLC - A/C No.4	do	83,000	0.33
		<b>22,718,261</b>	<b>89.00</b>

**Non-Voting Shareholders**

<b>Name of the Shareholder</b>	<b>Country of Residence</b>	<b>Number of Shares</b>	<b>Holding %</b>
Durdans Management Services Ltd	Sri Lanka	2,719,765	32.59
Employees Provident Fund	do	1,154,371	13.83
MJF Holdings Ltd	do	598,646	7.17
E W Balasuriya & Co. (Pvt) Ltd	do	330,619	3.96
Mr. D. Ratnayake	do	146,866	1.76
Mr. A. H. Munasinghe	do	138,614	1.66
Tudawe Engineering Services (Pvt) Ltd	do	91,986	1.10
Mr. D. A. Cabraal	do	82,500	0.99
Mr. S. S. Sithambaranathan	do	77,753	0.93
Mr. A. D. Tudawe	do	71,151	0.85
Mr. P. S. De Mel	do	70,822	0.85
People's Leasing & Finance PLC /Mr. P. A. I. S. Perera	do	70,100	0.84
Ms. T. T. Weerasinghe	do	68,485	0.82
Commercial Bank of Ceylon PLC A/C No. 04	do	61,100	0.73
Mr. D.P. L. De Mel	do	58,908	0.71
Saman Villas Limited	do	58,462	0.70
Mr. H A. Cabraal	do	50,000	0.60
Mr.G. D. M. Ranasinghe Jt Mrs. O. R. K. Ranasinghe	do	50,000	0.60
Mr. U. D. Wickremesooriya Jt. Mrs. S. F. Wickremesooriya	do	50,000	0.60
Hallsville Trading Group Inc	do	49,123	0.59
		<b>5,999,271</b>	<b>71.89</b>

## **CORPORATE INFORMATION**

### **Name of Company**

Ceylon Hospitals PLC

### **Brand Name**

DURDANS

### **Legal Form**

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

### **Company Registration Number**

PQ 113

### **Stocks Exchange Listing**

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

### **Registered Office**

No.03, Alfred Place, Colombo 03.

### **Bankers**

Bank of Ceylon  
Commercial Bank of Ceylon PLC  
DFCC Bank PLC  
Hatton National Bank PLC  
National Development Bank PLC  
Nations Trust Bank PLC  
Sampath Bank PLC  
Seylan Bank PLC  
Union Bank PLC  
People's Bank  
Cargills Bank Ltd

### **Auditors**

Messers.B.R.De Silva & Co.  
Chartered Accountants  
No. 22/4,Vijaya Kumaratunga Mawatha,  
Colombo 05.

### **Lawyers**

Mr. D. F. R. Jayamaha  
Hector Jayamaha Law Office,  
No. 228, Thimbirigasyaya Road,  
Colombo 05.

### **Secretaries**

Nexia Corporate Consultants (Pvt) Ltd  
No. 181, Nawala Road, Narahenpita,  
Colombo 05.

### **Registrars**

S S P Corporate Services (Pvt) Ltd  
No. 546, Galle Road,  
Colombo 03.